In concordance with previous findings, CD47-induced tumor immune evasion can be targeted by engineering non-pathogenic E. coli to specifically lyse and release anti-CD47 nanobodies in the TME, enhancing the activity of tumor-infiltrating T cells, promoting tumor regression, and preventing metastasis [139]. Here, CD47 is linked to neoplasm.